Agency hopes to inform healthcare providers and patients about comparisons of treatments for gastroesophagealreflux disease.
Medication for acid reflux disease is equally effective as surgery, according to the first in a series of reports on improving healthcare quality that were mandated by the 2003 Medicare Modernization Act.
An extensive analysis of previously reported data conducted by the Agency for Healthcare Research and Quality (AHRQ) found that the older histamine type-2 blockers are not as effective as the newer protein pump inhibitors (PPIs) that appeared in the 1990s, explained Kenneth Fink, director of the agency's evidence-based practice centers program.
According to Fink, there were some differences between traditional surgery, where part of the stomach is wrapped around the sphincter separating the esophagus from the stomach, cutting off the flow of acid, and PPIs. But the clinical importance of these differences is unclear, he continued.
The management of symptoms and increase in quality of life is similar between surgery and PPIs, he said, as are the long-term treatment benefits. Neither type of therapy was better at preventing cancer either.
The information in the AHRQ report does not contain any new information, according to Jon Spechler, professor of gastroenterology at the University of Texas Southwestern Medical Center. The PPIs offer very good treatment, and surgery is not necessary for most people, he said.
What's more, the effects of the surgery do not seem to last, after 10 years up to two-thirds of surgery patients are back on the medication, Spechler said.
But some experts have speculated that PPIs might have long-term side effects that would not appear until patients have used them for many more years, Spechler added.
For example, preventing acid from being pumped into the stomach up regulates the hormone that normally detects low levels of stomach acid, gastrin. As a result, people on PPIs have high levels of gastrin. Some people think this could cause growth problems, such as cancer, down the road.
There was not enough evidence about new, non-invasive endoscopic surgery techniques to compare them to either drugs or traditional surgery, Fink said.
Spechler said the endoscopic techniques were too new and that he would not recommend them yet.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.